WO2002010406A3 - Metalloproteinase-disintegrin polypeptides and methods of making and use thereof - Google Patents

Metalloproteinase-disintegrin polypeptides and methods of making and use thereof Download PDF

Info

Publication number
WO2002010406A3
WO2002010406A3 PCT/US2001/023734 US0123734W WO0210406A3 WO 2002010406 A3 WO2002010406 A3 WO 2002010406A3 US 0123734 W US0123734 W US 0123734W WO 0210406 A3 WO0210406 A3 WO 0210406A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
making
metalloproteinase
disintegrin
polypeptides
Prior art date
Application number
PCT/US2001/023734
Other languages
French (fr)
Other versions
WO2002010406A2 (en
Inventor
Robert F Dubose
Steven R Wiley
Roy A Black
Original Assignee
Immunex Corp
Robert F Dubose
Steven R Wiley
Roy A Black
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, Robert F Dubose, Steven R Wiley, Roy A Black filed Critical Immunex Corp
Priority to JP2002516322A priority Critical patent/JP2004507234A/en
Priority to EP01957300A priority patent/EP1307568A2/en
Priority to AU2001279060A priority patent/AU2001279060A1/en
Priority to MXPA03000522A priority patent/MXPA03000522A/en
Priority to US10/343,251 priority patent/US20040091473A1/en
Priority to CA002415436A priority patent/CA2415436A1/en
Publication of WO2002010406A2 publication Critical patent/WO2002010406A2/en
Publication of WO2002010406A3 publication Critical patent/WO2002010406A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Provided is a new disintegrin polypeptide, methods of making such polypeptides, and methods of using them to treat disintegrin-associated disorders and conditions and to identify agents that modulate Metalloproteinase-Disintegrin polypeptide activities.
PCT/US2001/023734 2000-07-28 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof WO2002010406A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002516322A JP2004507234A (en) 2000-07-28 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods for their production and use
EP01957300A EP1307568A2 (en) 2000-07-28 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
AU2001279060A AU2001279060A1 (en) 2000-07-28 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
MXPA03000522A MXPA03000522A (en) 2000-07-28 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof.
US10/343,251 US20040091473A1 (en) 2001-07-27 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
CA002415436A CA2415436A1 (en) 2000-07-28 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22183800P 2000-07-28 2000-07-28
US60/221,838 2000-07-28

Publications (2)

Publication Number Publication Date
WO2002010406A2 WO2002010406A2 (en) 2002-02-07
WO2002010406A3 true WO2002010406A3 (en) 2003-01-16

Family

ID=22829610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023734 WO2002010406A2 (en) 2000-07-28 2001-07-27 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof

Country Status (6)

Country Link
EP (1) EP1307568A2 (en)
JP (1) JP2004507234A (en)
AU (1) AU2001279060A1 (en)
CA (1) CA2415436A1 (en)
MX (1) MXPA03000522A (en)
WO (1) WO2002010406A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
JPWO2019187691A1 (en) * 2018-03-26 2021-03-25 株式会社カネカ Polypeptide having collagenase activity and its production method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083782A2 (en) * 2000-05-04 2001-11-08 Sugen, Inc. Novel proteases
WO2001094416A2 (en) * 2000-06-07 2001-12-13 Curagen Corporation Human proteins and nucleic acids encoding same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083782A2 (en) * 2000-05-04 2001-11-08 Sugen, Inc. Novel proteases
WO2001094416A2 (en) * 2000-06-07 2001-12-13 Curagen Corporation Human proteins and nucleic acids encoding same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BREAST CANCER RESEARCH AND TREATMENT. NETHERLANDS JUN 2000, vol. 61, no. 3, June 2000 (2000-06-01), pages 249 - 260, ISSN: 0167-6806 *
DATABASE MEDLINE [online] June 2000 (2000-06-01), ZHOU Q ET AL: "Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression.", XP002203869, Database accession no. NLM10966001 *
KUNTZ I D ET AL: "STRUCTURE-BASED MOLECULAR DESIGN", ACCOUNTS OF CHEMICAL RESEARCH, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 27, no. 5, May 1994 (1994-05-01), pages 117 - 123, XP000885741, ISSN: 0001-4842 *
NATH DEEPA ET AL: "Meltrin gamma (ADAM-9) mediates cellular adhesion through alpha6beta1 integrin, leading to a marked induction of fibroblast cell motility.", JOURNAL OF CELL SCIENCE, vol. 113, no. 12, June 2000 (2000-06-01), pages 2319 - 2328, XP002203866, ISSN: 0021-9533 *
PERRY A C F ET AL: "ANALYSIS OF TRANSCRIPTS ENCODING NOVEL MEMBERS OF THE MAMMALIAN METALLOPROTEASE-LIKE, DISINTEGRIN-LIKE, CYSTEINE-RICH (MDC) PROTEINFAMILY AND THEIR EXPRESSION IN REPRODUCTIVE AND NON-REPRODUCTIVE MONKEY TISSUES", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 312, no. PART 1, 15 November 1995 (1995-11-15), pages 239 - 244, XP002069782, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
EP1307568A2 (en) 2003-05-07
AU2001279060A1 (en) 2002-02-13
MXPA03000522A (en) 2003-10-06
JP2004507234A (en) 2004-03-11
WO2002010406A2 (en) 2002-02-07
CA2415436A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
HK1029936A1 (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
WO2001083755A3 (en) Human anti-cd40 antibodies and methods of making and using same
AU2210400A (en) Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
DE60118544D1 (en) METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ALPHA-ADRENEER RECEPTORS
DK0907631T3 (en) Inorganic ion receptor active compounds
BG100981A (en) Methods of producing effective recombinant serine inhibitors and uses of these ihibitors
ATE259512T1 (en) PORTABLE TELEPHONE AND POWER-ON METHOD
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
WO2000053774A3 (en) Metalloproteinases and methods of use therefor
WO1998022098A3 (en) Cpp32 inhibitors for regulating apoptosis
HUP0004544A2 (en) Process for preparation pharmaceutical composition combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders
TW200628612A (en) Substrates and assays for β-secretase activity
MXPA03003207A (en) MATERIALS AND METHODS TO MODULATE LIGAND BINDING/ENZYMATIC ACTIVITY OF agr;/bgr; PROTEINS CONTAINING AN ALLOSTERIC REGULATORY SITE.
AUPR066300A0 (en) The use of wireless application protocol for making trading decisions and executing transactions in real time
WO2002010406A3 (en) Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
WO2002010405A3 (en) A human disintegrin protein
HK1039793A1 (en) Caspase-14, an apoptotic protease, uncleic acids encoding and methods of use
WO1999041387A3 (en) Prostate-associated serine protease
WO2001094377A3 (en) Metalloprotease peptide substrates and methods
AU2061797A (en) A novel disintegrin metalloprotease and methods of use
ID26806A (en) NEW COMPOUNDS COMING FROM a-D-SILOSA, THE METHOD OF MAKING AND USING THERAPY
AU6977096A (en) Ketomethylene group-containing cysteine and serine protease inhibitors
WO2002100432A8 (en) Methods for the modulation of il-13
AU5873899A (en) Formation of a bridge in a micro-device
FR2734578B1 (en) ENZYME DEGRADING RHAMNOGALACTURONANE II, PROCESSES FOR OBTAINING THE ENZYME AND RHAMNOGALACTURONANE II AND USE OF THE ENZYME

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2415436

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000522

Country of ref document: MX

Ref document number: 2001279060

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001957300

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001957300

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10343251

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001957300

Country of ref document: EP